Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome
Advertisement
Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have discovered that cardiotrophin 1, a protein synthesized by muscle cells and adipose tissue, has a marked effect on fat and glucose metabolism. "These new findings add to those we already know on this compound such the anti-ischemic and cytoprotective effects showed in acute liver damage and solid organ transplants gives CT-1 great possibilities to be developed in various serious conditions", commented Pablo Ortiz, CEO of Digna Biotech.
The study was published in Cell Metabolism and further details were described in SciBX, the Biocentury/Nature publication. The researchers found that the administration of cardiotrophin 1 accelerates the elimination of fat from the adipose tissue and increases the rate at which fat is burnt in muscles. Treatment of obese and diabetic mice with cardiotrophin 1 increases energy expenditure, reduces food intake and corrects obesity and diabetes. Investigators noticed that, in addition to its effects on fat metabolism, cardiotrophin 1 promotes the entrance of glucose into the cells and increases the sensitivity to insulin. The investigation has been led by M. Bustos, J. Prieto and MJ Moreno-Aliaga at CIMA.
Cardiotrophin 1 is co-developed for its use in organ transplantation and tissue regeneration by Digna Biotech and Biotecnol (The Consortium). Both of the companies signed an Exclusive License and Option Agreement with Genentech, Inc on September 2009.
Pablo Ortiz remarked: "Cardiotrophin 1 showed a very interesting effect on fat metabolism which deserves to be explored in a clinical setting. We are ready to recruit healthy volunteers in the Phase I trial before the end of the year. Phase II in liver resection is scheduled for the second quarter of 2012. We are also confident that these new applications and the progress on the clinical development will allow us to forge partnerships with other biopharmaceutical companies to reach the patients as soon as possible".
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
University of Alberta chemical process licensed to GreenCentre holds promise for greener pharmaceutical production
Presence of nicotine and antidepressants detected in Antarctic waters - A study with the participation of IDAEA and IGME locates organic contaminants derived from human activity in inland and coastal waters of the frozen continent
Reverse negative impact of ultraviolet radiation on skin
Learning from Nature: How a fungus makes a hard job easier - Researchers analyze a fungal biosynthetic pathway and discover a capable enzyme
Anatomical barriers shield the brain from SARS-CoV-2 invasion at vulnerable interfaces - Absence of evidence for neurotropism and neuroinvasion of several SARS-CoV-2 variants including Omicron
Exposure to air pollution before and after birth may affect fundamental cognitive abilities
Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”
A clear path to better insights into biomolecules - 3D images with record-breaking resolution
Revolutionizing cancer research with diamonds
Heavy water tastes sweet - But not to mice
Ebola: New studies model a deadly epidemic
